The Possibilities of PrEP: Introduction

Slides:

Advertisements

Similar presentations

Dr. Carol Odula (Obs./Gyn.) May 7 th 2013 Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection.

Advertisements

From “What If” to “What Now” Perspectives on ARVs and the Future of Treatment and Prevention Mitchell Warren Executive Director, AVAC IAS 2011, Rome.

State of the Field Exploring 2015’s Top Ten List for the HIV Prevention Research Field Manju Chatani, Stacey Hannah, Mitchell Warren Thursday, January.

Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.

Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention

HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.

 Biomedical HIV Prevention strategies Wim Vandevelde European AIDS Treatment Group (EATG) European Community Advisory Board (ECAB) Conference on HIV Infection.

Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.

Use of Antivirals in Prevention Oral and Topical Prophylaxis

The potential and challenges of ARV-based HIV prevention: An overview

Microbicide Research: A Promising HIV/AIDS Prevention Strategy for Women Roberta Black, Ph.D. Division of AIDS, National Institute of Allergy and Infectious.

Introduction to HIV New Prevention Technologies (NPTs)

Slide 1 of 9 From J Marrazzo, MD, at Los Angeles, CA: April 22, 2013, IAS-USA. IAS–USA Jeanne Marrazzo, MD, MPH Professor of Medicine University of Washington.

What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,

When Will Women Have Choices? Sharon Hillier University of Pittsburgh School and Medicine Microbicide Trials Network IAS, Washington DC, July 26, 2012.

AIDS 2012 Where are we, and where are we going? Mitchell Warren Executive Director, AVAC August 15, 2012.

Ethics in a new era Microbicides 2012 Preconference Bridget Haire.

IAS July 1 The Caprisa 004 result in context Sheena McCormack Clinical Scientist MRC Clinical Trials Unit.

Microbicides and PrEP: Back to Basics Wednesday July 25, 2012 ADM Kashuba.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Pre-exposure Prophylaxis for HIV Prevention Efficacy and the importance of adherence Joanne Stekler,

New ARV-based prevention tools how the research is happening how we need to be involved Anna Forbes, MSS Consultant, HIV and women’s health HIV Research.

Antiretrovirals for HIV Prevention: Progress and Challenges Kenneth H. Mayer, M.D. Brown/Miriam/Fenway.

International Partnership for Microbicides ARV-Based Microbicides - Cause for Optimism Dr. Zeda Rosenberg, CEO Mexico City, 4 August 2008.

HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.

The tipping point: When do placebos become unethical? Bridget Haire.

Understanding the Rationale of the 2015 WHO Guidelines on PrEP IAS Satellite Session Heather Watts M.D. Office of the Global AIDS Coordinator July 18,

An overview of PrEP trials Bea Vuylsteke Institute of tropical Medicine, Antwerp, Belgium Marrakech, IUSTI 2016.

Global state of the science and implementation summary for oral PrEP

“No conflicts of interest to declare”

TDF-FTC QD + Raltegravir BID TDF-FTC QD + Lopinavir-ritonavir QD

Ian McGowan MD DPhil FRCP University of Pittsburgh Pittsburgh, PA, USA

Adherence and Acceptability for PrEP formulations

On Demand PrEP for Men at High Risk for HIV IPERGAY

UZ-UCSF Annual Research Day 8 April 2016

Pre-exposure Prophylaxis (PrEP)

HIV-Associated Weight Loss and Wasting

PrEP: A Case-by-Case Approach

HIV and the ART of Prevention

Updates on Emerging GLP-1 Receptor Agonists

Program Goals Overview of HIV Epidemic HIV and Communities of Color.

PrEP Effectiveness. Preexposure Prophylaxis Translating the Clinical Trials Into Clinical Practice.

Advances in HIV Care.

HIV Management: An Update on the Latest EACS Guidelines

Setting the Stage for PrEP Where are we now, and where should we go?

Treating HIV Infection:

PrEP in Women: Unique Considerations and Strategies

Translating Emerging HIV Data Into Clinical Practice

The Politics of PrEP The French Experience

Is it Time for a Paradigm Change in HIV Management?

PrEP Pre-Exposure Prophylaxis

Sinead Delany-Moretlwe, MBBCh PhD University of the Witwatersrand

HIV : New Agents, New Strategies

Initiating Pre-exposure Prophylaxis The PrEP Checklist

From Start to Finish: Initial and Ongoing Care for Men Receiving PrEP

Current and Future Perspectives on Migraine Prevention Therapy

Simplifying Insulin Delivery for Better Patient Outcomes in T2D

Rectal Gels for PrEP Are They an Option?

100 Partners PrEP[5] Efficacy 75% Adherence 81% 80

PrEP Ongoing Care.

When to Start and What to Use

Current Challenges in Managing Hemophilia

HIV Update 2018: A Front Row Seat

Module 6: WRAPPING UP Version: August 2018.

Managing Pain in the 21st Century

TRANSITION TO TLD – ZIMBABWE REPORT

Module 6: WRAPPING UP Version: June2019.

HIV Resistance in the Context of PrEP

Shared Decision Making in MS

HIV Preexposure Prophylaxis (PrEP) 2019

Presentation transcript:

The Possibilities of PrEP: Introduction

Preexposure Prophylaxis: Definition and Development

PrEP Efficacy Trials Containing Oral TDF

Effectiveness and Adherence in Trials of Oral and Topical Tenofovir-based Prevention

International PrEP Guidelines

International PrEP Guidelines (cont)

21 Countries Implementing Oral PrEP With TDF/FTC

Some Barriers to PrEP Implementation[a]

Implementation of PrEP

Populations Suitable for PrEP and Access to Treatment

PrEP as a Component of Various Prevention Initiatives

NHS England PrEP Implementation Trial

Adherence as a Crucial Component to PrEP

Concluding Remarks

Overview of Current Data on PrEP

Studies of PrEP: PROUD

Studies of PrEP: PROUD Results

Studies of PrEP: PROUD Inclusion Criteria and STI Rates

Studies of PrEP: PROUD Adherence

Studies of PrEP: IPERGAY Regimen

Studies of PrEP: IPERGAY Results

Studies of PrEP: IPERGAY Substudy in Infrequent Intercourse

PrEP Studies in Women

Future and Ongoing Trials, and Lessons to Date

Future Directions for PrEP Research

International AIDS Burden

PrEP and Adherence: A Meta-Analysis

TDF vs TAF

PrEP in Rectal vs Vaginal HIV Exposure

PrEP: Vaginal Topical Gel

Vaginal Ring PrEP: Results From ASPIRE

Injectable Cabotegravir: HPTN 083 Trial

Other PrEP Compounds: NNRTI and CCR5

Biodegradable Subcutaneous Implants

Concluding Remarks

Future Directions for PrEP Research

International AIDS Burden

PrEP and Adherence: A Meta-Analysis

TDF vs TAF

PrEP in Rectal vs Vaginal HIV Exposure

PrEP: Vaginal Topical Gel

Vaginal Ring PrEP: Results From ASPIRE

Injectable Cabotegravir: HPTN 083 Trial

Other PrEP Compounds: NNRTI and CCR5

Biodegradable Subcutaneous Implants

Concluding Remarks

The Possibilities of PrEP: Concluding Remarks

PrEP: Concluding Remarks

Abbreviations

Abbreviations (cont)